PDS Biotechnology Shares Outstanding History (PDSB)
PDS Biotechnology reported 54.9M shares outstanding at the end of fiscal 2025.
View full PDS Biotechnology company overviewPDS Biotechnology annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 54.9M | 16.9M | +44.46% |
| 2024 | 2024-12-31 | 38.0M | 4.9M | +14.78% |
| 2023 | 2023-12-31 | 33.1M | 2.9M | +9.69% |
| 2022 | 2022-12-31 | 30.2M | 1.7M | +6.05% |
| 2021 | 2021-12-31 | 28.4M | 6.2M | +27.79% |
| 2020 | 2020-12-31 | 22.3M | 17.0M | +321.52% |
| 2019 | 2019-12-31 | 5.3M | 1.9M | +54.55% |
| 2018 | 2018-12-31 | 3.4M | 1.9M | +121.40% |
| 2017 | 2017-12-31 | 1.5M | 97,534.45 | +6.75% |
| 2016 | 2016-12-31 | 1.4M | 5,383.55 | +0.37% |
| 2015 | 2015-12-31 | 1.4M | 1.4M | +1606.32% |
| 2014 | 2014-12-31 | 84,423.75 | — | — |
PDS Biotechnology quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 55.9M | 9.3M | +19.92% |
| Q1 2026 | 2026-03-31 | 55.8M | 10.4M | +22.82% |
| Q4 2025 | 2025-12-31 | 54.9M | 16.9M | +44.46% |
| Q3 2025 | 2025-09-30 | 47.7M | 10.9M | +29.56% |
| Q2 2025 | 2025-06-30 | 46.6M | 9.9M | +26.79% |
| Q1 2025 | 2025-03-31 | 45.4M | 8.8M | +23.90% |
| Q4 2024 | 2024-12-31 | 38.0M | 4.9M | +14.78% |
| Q3 2024 | 2024-09-30 | 36.8M | 5.8M | +18.74% |
| Q2 2024 | 2024-06-30 | 36.8M | 5.9M | +19.15% |
| Q1 2024 | 2024-03-31 | 36.7M | 6.0M | +19.38% |
| Q4 2023 | 2023-12-31 | 33.1M | 2.9M | +9.69% |
| Q3 2023 | 2023-09-30 | 31.0M | 2.5M | +8.96% |
| Q2 2023 | 2023-06-30 | 30.9M | 2.4M | +8.47% |
| Q1 2023 | 2023-03-31 | 30.7M | 2.3M | +7.99% |
| Q4 2022 | 2022-12-31 | 30.2M | 1.7M | +6.05% |
| Q3 2022 | 2022-09-30 | 28.5M | 23,621 | +0.08% |
| Q2 2022 | 2022-06-30 | 28.5M | 40,779 | +0.14% |
| Q1 2022 | 2022-03-31 | 28.5M | 6.2M | +27.71% |
| Q4 2021 | 2021-12-31 | 28.4M | 6.2M | +27.79% |
| Q3 2021 | 2021-09-30 | 28.4M | 6.2M | +27.73% |
| Q2 2021 | 2021-06-30 | 28.4M | 13.1M | +84.99% |
| Q1 2021 | 2021-03-31 | 22.3M | 6.9M | +45.13% |
| Q4 2020 | 2020-12-31 | 22.3M | 17.0M | +321.52% |
| Q3 2020 | 2020-09-30 | 22.3M | 17.0M | +321.71% |
| Q2 2020 | 2020-06-30 | 15.4M | 10.2M | +196.70% |
| Q1 2020 | 2020-03-31 | 15.4M | 10.2M | +196.75% |
| Q4 2019 | 2019-12-31 | 5.3M | 1.9M | +54.55% |
| Q3 2019 | 2019-09-30 | 5.3M | 3.7M | +237.00% |
| Q2 2019 | 2019-06-30 | 5.2M | 3.6M | +230.53% |
| Q1 2019 | 2019-03-31 | 5.2M | 3.6M | +231.11% |
| Q4 2018 | 2018-12-31 | 3.4M | 1.9M | +121.40% |
| Q3 2018 | 2018-09-30 | 1.6M | 23,446.4 | +1.52% |
| Q2 2018 | 2018-06-30 | 1.6M | 24,943.2 | +1.62% |
| Q1 2018 | 2018-03-31 | 1.6M | 111,739.75 | +7.70% |
| Q4 2017 | 2017-12-31 | 1.5M | 97,534.45 | +6.75% |
| Q3 2017 | 2017-09-30 | 1.5M | 97,198.7 | +6.72% |
| Q2 2017 | 2017-06-30 | 1.5M | 98,990.9 | +6.86% |
| Q1 2017 | 2017-03-31 | 1.5M | 9,910.8 | +0.69% |
| Q4 2016 | 2016-12-31 | 1.4M | 5,383.55 | +0.37% |
| Q3 2016 | 2016-09-30 | 1.4M | 1.4M | +1612.51% |
| Q2 2016 | 2016-06-30 | 1.4M | 1.4M | +1608.61% |
| Q1 2016 | 2016-03-31 | 1.4M | — | — |
| Q4 2015 | 2015-12-31 | 1.4M | — | — |
| Q3 2015 | 2015-09-30 | 84,423.75 | — | — |
| Q4 2014 | 2014-12-31 | 84,423.75 | — | — |
PDS Biotechnology shares outstanding trends
Over the last five reported fiscal years, PDS Biotechnology's shares outstanding moved from 22.3M to 54.9M, a change of 32.6M. The latest reported quarter, Q2 2026, shows 55.9M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PDS Biotechnology filings at SEC.gov ↗